ADX 102

Drug Profile

ADX 102

Alternative Names: ADX-102; NS 2; NS-2-Aldeyra

Latest Information Update: 25 Apr 2017

Price : $50

At a glance

  • Originator Aldeyra Therapeutics
  • Class Anti-inflammatories; Eye disorder therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunosuppressants; Malondialdehyde inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sjogren-Larsson syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Allergic conjunctivitis; Sjogren-Larsson syndrome; Uveitis
  • Preclinical Contact dermatitis; Mucositis
  • Research Inborn error metabolic disorders

Most Recent Events

  • 20 Apr 2017 ADX 102 receives Orphan Drug status for Sjogren-Larrson syndrome in USA
  • 18 Apr 2017 Aldeyra Therapeutics completes enrolment in its phase II trial in Allergic conjunctivitis in USA (Ophthalmic)
  • 25 Jan 2017 Aldeyra Therapeutics plans a phase III trial for Sjogren-Larsson Syndrome in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top